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Abstract
Background: Parkinson’s disease (PD) results from a loss of dopamine in the brain, leading to movement
dysfunctions such as bradykinesia, postural instability, resting tremor and muscle rigidity. Furthermore, dopamine
deficiency in PD has been shown to result in maladaptive plasticity of the primary motor cortex (M1). Progressive
resistance training (PRT) is a popular intervention in PD that improves muscular strength and results in clinically
significant improvements on the Unified Parkinson’s Disease Rating Scale (UPDRS). In separate studies, the
application of anodal transcranial direct current stimulation (a-tDCS) to the M1 has been shown to improve motor
function in PD; however, the combined use of tDCS and PRT has not been investigated.
Methods/design: We propose a 6-week, double-blind randomised controlled trial combining M1 tDCS and PRT of the
lower body in participants (n= 42) with moderate PD (Hoehn and Yahr scale score 2–4). Supervised lower body PRT
combined with functional balance tasks will be performed three times per week with concurrent a-tDCS delivered at 2
mA for 20 minutes (a-tDCS group) or with sham tDCS (sham group). Control participants will receive standard care
(control group). Outcome measures will include functional strength, gait speed and variability, balance, neurophysiological
function at rest and during movement execution, and the UPDRS motor subscale, measured at baseline, 3 weeks (during),
6 weeks (post), and 9 weeks (retention). Ethical approval has been granted by the Deakin University Human Research
Ethics Committee (project number 2015-014), and the trial has been registered with the Australian New Zealand Clinical
Trials Registry (ACTRN12615001241527).
Discussion: This will be the first randomised controlled trial to combine PRT and a-tDCS targeting balance and gait in
people with PD. The study will elucidate the functional, clinical and neurophysiological outcomes of combined PRT and
a-tDCS. It is hypothesised that combined PRT and a-tDCS will significantly improve lower limb strength, postural sway,
gait speed and stride variability compared with PRT with sham tDCS. Further, we hypothesise that pre-frontal cortex
activation during dual-task cognitive and gait/balance activities will be reduced, and that M1 excitability and inhibition
will be augmented, following the combined PRT and a-tDCS intervention.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12615001241527. Registered on 12
November 2015.
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Background
Parkinson’s disease (PD) is a progressive neurodegenera-
tive movement disorder characterised by depletion of
dopamine in the substantia nigra, resulting in physical
symptoms such as bradykinesia, postural instability, rest-
ing tremor and muscle rigidity. PD is the second most
common neurodegenerative disorder [1], affecting 1 % of
people older than 60 years of age [2], which is of particular
concern as populations age. PD causes significant impair-
ments in gait and balance, which are often unresolved by
standard dopamine pharmacological treatment [3] and re-
sult in reduced quality of life and increased risk of falls [4].
There is growing evidence for the use of progressive
resistance training (PRT) to improve gait and lower limb
muscle strength in PD [5]. The inclusion of other func-
tional tasks, such as balance training, in PRT pro-
grammes has also been shown to decrease postural
sway, reduce the risk of falls, and improve quality of life
[6]. Importantly, functional PRT programmes have been
shown to induce neuroplastic changes in the primary
motor cortex (M1) of both healthy individuals [7] and
people with PD [8]. This is of particular interest, as mal-
adaptive M1 plasticity in patients with PD has been
linked to poorer outcomes in motor learning and move-
ment control [9, 10]. Evidence derived from transcranial
magnetic stimulation (TMS) studies has demonstrated
that patients with PD present with increased cortical
excitability and reduced inhibition at rest, which is evi-
denced by lower motor threshold, increased motor
evoked potential (MEP) amplitude, reduced short-
interval intra-cortical inhibition (SICI) [10] reduced si-
lent period [11]. Furthermore, reduced intra-cortical fa-
cilitation and absence of MEP size increase during
contraction suggests defective facilitatory cortical in-
puts, particularly for movement execution [12]. In
addition, the absence of a putative neuroplastic re-
sponse following paired associative stimulation [13, 14],
as compared with healthy control subjects, suggests
that the facilitation of M1 plasticity in patients with PD
may play an important role in the restoration and
maintenance of motor performance.
Transcranial direct current stimulation (tDCS) is a form
of non-invasive brain stimulation that has been shown to
modulate excitability of the M1 in a polarity-specific man-
ner when applied for short periods (10–20 minutes).
When anodal tDCS (a-tDCS) is applied to the M1,
there is a transient increase (up to 90 minutes) in ex-
citability and reduction SICI of underlying neurons
[15], as well as widespread changes in activation of
cortical and subcortical areas [16]. There is substan-
tial evidence to suggest that the application of a-tDCS
to the M1 results in improved motor function in
healthy populations, including increased performance
in skill and strength tasks [17, 18], and this may be
especially true when tDCS is applied during concur-
rent motor practice or training [19].
The use of tDCS as an independent intervention in PD
has produced promising results, with evidence for im-
proved working memory and executive function [20, 21],
reduced bradykinesia, and increased walking speed follow-
ing tDCS [22]. Importantly, clinically significant im-
provements in the motor component of the Unified
Parkinson’s Disease Rating Scale (UPDRS) have been
reported following bilateral a-tDCS of the M1 [23]. A
recent pilot study of eight participants reported for
the first time that combined gait training and M1 a-
tDCS showed promising improvements in walking
and balance measurements, but the researchers in
that study concluded that larger trials were required
to produce definitive results [24].
Given the existing evidence for enhancements in neu-
roplasticity and motor performance following both PRT
and tDCS as independent treatments, it is reasonable to
conclude that the combination of these two interven-
tions may further augment functional benefits in pa-
tients with PD. Indeed, a combination of a-tDCS and
motor training appears to produce a compounding effect
on motor performance and neurophysiological adapta-
tions in healthy populations [25, 26] and stroke-affected
individuals [27, 28]; however, the application of a-tDCS
during PRT and balance training in PD is yet to be
investigated.
Methods/design
Aims
The primary aim of this pilot study is to determine the
effects of a 6-week lower limb balance and PRT inter-
vention with concurrent a-tDCS on gait, balance,
strength and UPDRS motor scores in patients with PD.
In addition, we will investigate neurophysiological adap-
tations in M1 excitability and pre-frontal cortex (PFC)
activation as potential underlying mechanisms. It is
hypothesised that the combination of PRT and a-tDCS
will produce favourable functional motor outcomes and
neuroplasticity beyond the effects of PRT alone.
Eligibility and recruitment
The recruitment, screening and randomisation process
is shown in Fig. 1. Potential participants will be recruited
on a voluntary basis with the assistance of the Australian
Parkinson’s Disease Registry and neurology clinics within
the Melbourne metropolitan area. All participants will
provide written informed consent as well as written ap-
proval from their general practitioner before partaking
in physical exercise. Prior to enrolment in the study, a
series of screening questionnaires will be completed by
telephone to determine eligibility.
The following inclusion criteria will be applied:
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1. Diagnosed with PD by an independent neurologist
2. Moderate motor symptoms (score between 2 and 4
on the Hoehn and Yahr scale, as assessed by an
independent neurologist and confirmed at initial
assessment by a blinded researcher)
3. Stable drug regime for the full duration of the study
and the 6 weeks preceding the study
4. Self-reported history of one or more falls in the last
24 months
5. Not currently undertaking a regular exercise
programme
Potential participants will be excluded if they present
with any of the following:
1. Severe motor impairments or injuries that will
impair the ability to perform lower limb PRT
(confirmed at initial assessment by blinded
researcher)
2. Previously diagnosed neurological condition separate
from PD (stroke, dementia, epilepsy)
3. Metal implants in the head (i.e., deep brain
stimulator or aneurysm clips), which are
contraindicated with non-invasive brain stimulation
techniques
Randomisation and blinding
Once recruited, simple randomisation using a compu-
terised sequence generator will be used to allocate par-
ticipants to one of three study groups (a-tDCS, sham or
control). Opaque envelopes will be used to conceal the
group allocation, which will not be revealed until after
all data have been analysed. A researcher who is
otherwise removed from the study will program the
tDCS machine before PRT sessions to ensure double-
blinding of both researcher and participant. Participants
allocated to the control group will be notified of their al-
location and will be asked to attend assessment sessions
only.
Study overview
The study will run for a period of 9 weeks in total, in-
cluding a 6-week intervention period and a 3-week
follow-up. Participants will be randomly allocated to one
of three groups:
1. a-tDCS (required to perform PRT and balance
training while receiving a-tDCS)
2. Sham (required to perform PRT and balance training
while receiving sham tDCS)
3. Control (to receive standard care)
Exercise sessions will include PRT and balance training
for a duration of approximately 40 minutes, and they
will be completed on 3 non-consecutive days per week
(18 sessions in total). Assessment sessions to evaluate
outcome measures will take place at four time points:
baseline (T0), mid-intervention at 3 weeks (T3), post-
intervention at 6 weeks (T6) and retention at 9 weeks
(T9). Assessment sessions will take approximately 3 h
and will occur at the same time of day for each time
point. All sessions will take place at the Deakin Univer-
sity Burwood campus in a specialised clinical exercise
gym and laboratory facility. The control group will re-
ceive standard care for the duration of the study and will
be required only to attend the assessment sessions. Fig-
ure 2 provides an overview of the study time frame and
sessions. For the duration of the study, all participants
will continue with their usual care and medications as
prescribed by their physician. Any changes in medication
status during the trial will be documented, and partici-
pants will be allowed to continue with the programme.
Intervention
Strength and balance training
Participants will be required to attend PRT and balance
training sessions at Deakin University Burwood campus
three times per week, on non-consecutive days, for 6
weeks. All PRT exercises will be aimed at the lower body
and will include the following: leg press performed on
fixed pneumatic gym equipment (Air300; Keiser, Fresno,
CA, USA) (see Fig. 3); sit to stand, progressing to body
weight squat and addition of weight vest (5, 10 or 15 kg)
(see Fig. 4); standing bilateral calf raise, progressing to
unilateral calf raise and weighted vest (se Fig. 5); and
seated unilateral dorsiflexion with free weight dumb-bell
(see Fig. 6).
Fig. 1 Flow diagram of recruitment, screening and randomisation
process. a-tDCS anodal transcranial direct current stimulation
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Fig. 2 Study timeline (a) and Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT 2013) diagram (b) illustrate the schedule of
enrolment, interventions and assessments. fNIRS functional near-infrared spectroscopy, FTSTS Five Times Sit-to-Stand Test, PRT progressive resistance
training, tDCS transcranial direct current stimulation, TMS transcranial magnetic stimulation, TUG Timed Up and Go Test, UPDRS Unified Parkinson’s
Disease Rating Scale
Fig. 3 Example of seated leg press
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Participants will perform three sets of six to eight rep-
etitions of each exercise, with resistance set at 70 % of
their recorded single-repetition maximum (1RM). Repe-
tition timing will be externally paced by an audible
metronome consisting of 3-second concentric and 3-
second eccentric contractions. For each exercise, resist-
ance will be increased by 5 % when all sets can be com-
pleted with correct repetition timing and technique, as
assessed by a trained exercise physiologist.
Between each set of exercises, participants will per-
form a functional balance task:
1. Tandem stance, 4 × 15 seconds alternating the
leading foot
2. Single-leg stance, 4 × 15 seconds alternating the
leading foot
3. Tandem walk, 3 × 12 steps, heel to toe, in a straight line
4. Hurdle walk, six laps of four hurdles (height = 30 cm)
Fig. 4 Example of body weight squat
Fig. 5 Example of standing bilateral calf raise
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Stance tasks will be performed with the assistance
of the trainer if required and will be progressed by
using unstable foam surfaces, duraDiscs (AOK Health,
Newcastle, Australia), performing with the eyes
closed, and receiving multi-directional perturbations.
Walking tasks will be progressed by performing a
concurrent dual task (naming colours, cities, coun-
tries, and so forth), adding 1-kg ankle weights, and
being instructed to ‘pause’ and ‘reverse’ mid-task. Par-
ticipants will advance to the next progression when
the exercise physiologist deems that they can compe-
tently complete the task.
Transcranial direct current stimulation
A tDCS Stimulator Model 101 (TCT Research Limited,
Hong Kong, China) will be used to deliver a-tDCS and
sham tDCS. For a-tDCS, a current of 2 mA will be deliv-
ered through two 50-cm2 electrodes, producing a
current density of 0.04 mA/cm2. The anode will be
soaked in saline and placed centrally over the left and
right motor representation of the lower limb, as pre-
determined with TMS, and secured with adjustable rub-
ber straps. The cathode will be placed on the right tra-
pezius muscle at the base of the neck, with Ten20
conductive gel (Weaver and Company, Aurora, CO,
USA) used to secure the rubber electrode directly onto
the skin. Figure 7 demonstrates the electrode montage.
Stimulation will commence at the beginning of the train-
ing session and will be delivered for a duration of 20
minutes (typically ceasing approximately halfway
through the session). Bioelectrical impedance will be
monitored throughout the stimulation protocol and will
not exceed 55 kΩ. Sham tDCS will involve an identical
electrode montage, with stimulation ceasing after a 20-
second ramp-up period to provide equivalent scalp sen-
sation. A pseudo-stimulation feature built into the direct
current stimulator allows for the device to be pre-
programed to deliver sham stimulation while maintain-
ing identical appearance, operation and screen prompts.
This was conducted prior to each session by a laboratory
assistant, enabling double-blinding of both researcher
and participant.
Compliance requirements
Participants will be required to complete a minimum of
16 of the 18 scheduled training sessions (representing >85
% attendance). Testing of outcome measures (T0, T3, T6
and T9) will be completed within 72 h of the scheduled
time point, determined from the commencement of the
training programme.
Outcome measures
Functional strength of the lower limb
Participants will perform 1RM tests to assess maximal
voluntary strength of the lower limb muscles. A standard
leg press and leg extension exercise will be performed
on fixed pneumatic gym equipment (Air300; Keiser).
Plantarflexion will be measured bilaterally on the seated
Fig. 6 Example of unilateral dorsiflexion with free-weight dumb-bell
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leg press by placing the toes on the footplate and using
the ankle dorsiflexion to press the plate forward while
maintaining 180-degree knee extension. The unweighted
movement distance is marked on the equipment, allow-
ing the researcher to ensure that full range of movement
is maintained during maximal attempts. Dorsiflexion will
be measured unilaterally while the participant is seated
with the heel positioned on a 25-cm step. A custom-
made static strap weighted with an adjustable dumb-bell
will be placed over the metatarsophalangeal joint, and
the participant will be required to lift the dumb-bell
smoothly through 45 degrees of dorsiflexion, measured
by the researcher with a goniometer. All exercises have
been chosen carefully to minimise any risk of falling or
injury whilst being performed.
An initial starting resistance of approximately 20 %
1RM will be estimated by the researcher to familiarise
the participant with the movement, and five to ten repe-
titions will be performed to provide a warm-up. The re-
searcher will then select an appropriate resistance for a
near-maximal effort, and the participant will be required
to perform a single repetition of the exercise while main-
taining correct technique. The resistance will be in-
creased in 5–10 % increments as appropriate, until the
participant can no longer perform a full repetition. Two
minutes of rest will separate each attempt, and verbal
encouragement will be provided. The highest resistance
used to perform a successful repetition will be recorded
as the 1RM in kilograms.
Functional assessments
Motor function specific to PD will be assessed with sec-
tion III of the UPDRS-III. The same independent assessor
will perform the test at all time points and will be blinded
to the intervention group. The assessment will be per-
formed at the same time of day and will precede all other
tests to ensure fatigue does not confound performance.
A Timed Up-and-Go Test (TUG) will also be per-
formed to assess motor function and speed [29]. Partici-
pants will be asked to rise from a 46-cm chair, walk
around a plastic cone located 3 m away and return to
the chair as quickly as possible. The arms of the chair
may be used if necessary. The test ends when the par-
ticipant assumes the original seated position, and time is
recorded. Regular enclosed footwear will be worn, and
customary walking aids may be used if required. The
average time in seconds from three trials will serve as
the TUG score.
The Berg Balance Scale will be used to assess func-
tional balance [30]. The assessment will take ap-
proximately 20 minutes and will consist of 14 static
and dynamic balance tasks which are scored from 0
to 4 by a trained exercise physiologist. The same as-
sessor will perform the test at all time points and
will be blinded to the intervention group. High valid-
ity and reliability of the Berg Balance Scale in neuro-
logical patient populations have previously been
established [31].
The Five Times Sit-to-Stand Test (FTSTS) will be used
to assess mobility and lower limb acceleration [32]. Par-
ticipants will be seated in a 46-cm chair without arm-
rests and will be asked to begin with their arms folded
across the chest and their back upright against the back-
rest. Participants will perform five repetitions of moving
from the seated position to standing, with the legs fully
extended and hip and knee joints, as quickly as possible.
The total time taken to complete five repetitions will be
recorded in seconds. An inertial measurement unit
(Nanotrak; Catapult Innovations, Docklands, Australia)
worn on the right hip, sampling accelerations and gy-
rations at 100 Hz, will be used to determine vertical
acceleration [33]. Previous researchers have reported
high validity and reliability of the FTSTS in patients
with PD [34].
Fig. 7 Example of electrode montage for anodal transcranial direct current stimulation
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Gait
Gait will be assessed using the ProtoKinetics Zeno 4.9-
metre walkway (ZenoMetrics LLC, Peekskill, NY, USA).
The walkway has a 2-foot-wide grid of pressure-sensing
pads with a spatial resolution of 0.5 cm and a sampling
frequency of 120 Hz. Participants will be asked to per-
form the walking trials at their preferred walking speed
while wearing comfortable footwear. Two different gait
conditions will be assessed: (1) normal walking and (2)
walking while counting backward in 7s from a random
three-digit number, termed dual-task gait. Three trials
of each condition will be performed in random order. A
trial begins by sitting silently on a chair for 30 seconds,
then standing up and walking to a starting line located 1
m from the walkway. From the start line, the participant
is asked to walk up and back four times to another line
1 m beyond the end of the walkway before returning to
the seated position. The 30-second rest periods between
each trial allow for accurate functional near-infrared
spectroscopy (fNIRS) hemodynamic brain imaging (see
‘Functional near-infrared spectroscopy’ section below for
details). The mean asymmetry and variability will be cal-
culated using all of the steps of all of the trials for a
given condition: step velocity (in meters/second), step
duration (in seconds) step length (in centimetres),
double support time (in seconds) and stride width (in
centimetres). Step variability will be calculated on the
basis of residuals, as suggested in previous literature
[35]. Gait assessments using instrumented walkways
have been shown to be repeatable in older adults [35,
36].
While undertaking the gait assessments, the partici-
pants will be asked to wear an inertial measurement unit
on an elastic belt (Nanotrak) for sampling of accelera-
tions and gyrations at 100 Hz at lumbar vertebrae L3–
L5, in line with the spinous processes. Harmonic ratio
[37] and multi-scale sample entropy will be calculated
from the recorded vertical and resultant signals [38].
These inertial measurement unit-based variables have
previously been shown to be repeatable [38].
Posturography
Static balance will be assessed with a 45-second bipedal
standing test in three separate conditions: (1) eyes open,
(2) eyes closed and (3) dual-task balance (eyes open
while counting backwards in serial 7s from a random
three-digit number). All tests will be conducted at pre-
ferred stance width, which will be recorded at baseline
and maintained during all subsequent tests. A black dot
(10-cm diameter) printed on white paper will be affixed
3 m in front of the participants at eye height, and the
participants will be asked to fix their gaze on the dot
while undertaking the eyes-open tests. Again, 30-second
rest periods between each trial will be provided for
concurrent fNIRS sampling. The measurement will be
conducted on a portable force plate (AccuGait; AMTI,
Watertown, MA, USA) sampling ground reaction forces
at 500 Hz. Instantaneous centre of pressure will be
calculated on the basis of recorded signals, and centre-
of-pressure travel velocity (millimetres/second) will be
calculated to represent static balance. The repeatability
of centre-of-pressure travel analyses has been demon-
strated in previous studies [39].
Transcranial magnetic stimulation and electromyography
Corticospinal excitability and intra-cortical inhibition of
the tibialis anterior (TA) muscle will be assessed using
two Magstim 2002 stimulators (Magstim, Whitland, UK)
connected to a 110-mm, concave, double-cone coil
(maximum output 1.4 T). The coil will be positioned
with anterior-to-posterior current flow, and sites near
the estimated right TA motor representation (approxi-
mately 1–3 cm lateral and anterior to the vertex) will be
explored to determine the optimal site, which will be
marked on the scalp with a permanent marker. Resting
motor threshold (RMT) and active motor threshold
(AMT) will be defined as the lowest stimulator output
required to achieve an MEP with an amplitude greater
than 0.05 mV and 0.20 mV in six of ten stimuli, respect-
ively. Corticospinal excitability will be determined by de-
livering ten single-pulse stimuli at suprathreshold
intensities of 1.3 × RMT and 1.5 × RMT. In accordance
with previous literature [40], SICI will be determined by
delivering ten paired-pulse stimuli, with the conditioning
stimulus set at 0.8 × RMT, the test stimulus set at 1.3 ×
RMT, and an interstimulus interval of 3 milliseconds.
Intra-cortical inhibition will be determined by calculat-
ing the SICI ratio (average paired-pulse MEP amplitude/
average single-pulse MEP amplitude); thus, SICI ratio
values closer to 1 will represent lower levels of intra-
cortical inhibition, while SICI ratio values closer to 0 will
represent higher levels of intra-cortical inhibition. The
total of 30 stimuli (20 single pulses and 10 paired pulses)
will be delivered in sets of 5 in a randomised order.
Once the TMS protocol has been completed with the TA
muscle at rest, the same protocol will be repeated in an ac-
tive muscle state while the participant maintains a low-level
background contraction (10 % of maximum force). The
participant’s maximal voluntary isometric contraction
(MVIC) of the right TA will first be determined using a
force transducer (LMD500; Futek, Irvine, CA, USA)
mounted in a custom-made timber frame. The participant
will be seated with the knee and ankle positioned at 90 de-
grees and the transducer positioned above the distal end
of the metatarsals. The participant will be instructed to
dorsiflex at the ankle with the base of the heel remaining
on the floor, producing an isometric contraction against
the force transducer. The peak force obtained from three
Hendy et al. Trials  (2016) 17:326 Page 8 of 13
maximal efforts with 2 minutes rest between attempts
with the highest force output will be recorded as the par-
ticipant’s MVIC. Verbal encouragement will be provided,
and visual feedback of force will be visible on a monitor
directly in front of the participant at eye level. To
complete the TMS protocol in the active muscle condi-
tion, 10 % of the MVIC will be calculated and indicated by
a line on the monitor. The participant will be asked to
maintain the force feedback level with the line while TMS
is delivered, with short rest periods (5–10 seconds) be-
tween each set of five stimuli. AMT will be defined as the
lowest stimulator output required to achieve an MEP with
an amplitude greater than 0.2 mV in six of ten stimuli.
Maximal compound waves (M-waves) will be collected
during each session and used to normalise MEP re-
sponses. This method prevents any changes in peripheral
muscle excitability acting as a confounder when deter-
mining corticospinal excitability [41]. A DS7A constant
current electrical stimulator (Digitimer, Welwyn Garden
City, UK) will be used to deliver supramaximal stimula-
tion to the common peroneal nerve. The head of the
fibula will be palpated, and a stimulating bar will be po-
sitioned directly inferior, with light pressure applied.
Stimulation will be delivered at increasing current
strengths until the muscle response reaches a plateau,
then increased 10–20 % to ensure maximal stimulation
is achieved. The largest resulting peak-to-peak muscle
response will be reported as maximal M-wave amplitude.
The M-wave will be obtained in both resting and active
(10 % MVIC) muscle conditions and will be used to nor-
malise resting and active MEPs, respectively.
All muscle responses (MEPs and M-waves) will be re-
corded using surface electromyography (sEMG). The
area of electrode placement will be shaved to remove
hair, rubbed with abrasive gel to remove dead skin, and
then cleaned with 70 % isopropyl alcohol. Bipolar gel
Ag-AgCl electrodes (8-mm diameter, model E258S; BIO-
PAC Systems, Goleta, CA, USA) will be placed over the
TA muscle belly with an inter-electrode distance of 2
cm. A grounding electrode will be placed over the pa-
tella and used as a common reference. The electrode
sites will be marked with a permanent marker, measured
in reference to the tibial tuberosity, and photographed to
ensure consistent electrode placement between sessions.
All cables will be fastened with tape to prevent move-
ment artifact. All sEMG signals (including MEPs) will be
amplified (×1000) with band-pass filtering between 13
Hz and 1000 Hz, digitised online at 2 KHz for 500 milli-
seconds, and recorded and analysed using PowerLab 4/
35 (ADInstruments, Bella Vista, Australia).
Functional near-infrared spectroscopy
Mechanisms underlying difficulties in dual-task gait and
balance are largely unclear. However, the PFC, which is
primarily involved in attention and executive function, is
also involved in human balance and locomotion [42],
which likely plays an important role. Although attention
and executive function that depend on the PFC are often
affected in PD [43–45], patients may rely more on the
PFC because of reduced movement automaticity of dys-
functional basal ganglia circuits [46–48]. Consequently,
altered functioning of the PFC during dual-task gait and
balance in PD might explain the difficulties of patients
with PD and therefore will be examined in this study
using fNIRS.
fNIRS neuroimaging uses optical technology to meas-
ure the relative concentrations of oxygenated haemoglo-
bin (O2Hb) and deoxygenated haemoglobin (HHb) in
the cortical layer microcirculation [49], producing cor-
tical activation data consistent with data obtained from
functional magnetic resonance imaging [50, 51]. Portable
fNIRS has successfully been used to measure PFC activa-
tion during dual-task walking in patients with PD [52]
and in other populations [53–55]. A PortaLite™ fNIRS
system (Artinis Medical Systems, Elst, The Netherlands)
will be used to assess PFC activation during several
tasks, including counting backwards in 7s from a ran-
dom three-digit number while seated and during the
simple and dual-task gait-and-balance assessments de-
scribed in the previous section.
The PortaLite™ device has three transmitters and one
receiver, with transmitter-receiver distances of 30, 35
and 40 mm. Near-infrared light is transmitted with two
wavelengths, 760 nm and 850 nm, and data will be sam-
pled with a frequency of 10 Hz. The PortaLite™ device
uses wireless technology (Bluetooth, Kirkland, WA,
USA), allowing participants to perform the tasks without
restriction of wires. Since a previous preliminary study
showed no significant differences between left- or
right-side PFC activation during dual-task walking in
PD [52] the PortaLite™ device will be placed on the
left forehead F3 site using the international 10–20
electroencephalography system. This location will tar-
get the left Brodmann’s areas 9 and 10, which corres-
pond to the dorsolateral and anterior PFC [56, 57].
The device will be shielded from ambient light by
covering the forehead with a black piece of fabric.
Oxysoft software (Artinis Medical Systems) will be
used for data collection and analysis.
On the basis of different absorption spectra, concen-
tration changes of O2Hb and HHb in the targeted PFC
area will be calculated from the changes in detected
light intensity. This is done using the modified Beer-
Lambert law, assuming constant scattering [58]. The
differential path length factor, which accounts for the
increased distance travelled by light due to scattering,
will be set to 6 for all participants. For analysis, O2Hb
and HHb signals of the three channels (the three
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transmitter-receiver distances) will be averaged. The
moving SD-based movement artifact reduction algo-
rithm method will be used within each trial to remove
movement artifacts and other noise from the fNIRS sig-
nals [59]. The threshold for artifact detection will be set
to 0.45 for O2Hb and 0.18 for HHb [52], with a window
length for moving SD calculation at 0.5 seconds and a
window length for artifact correction (locally weighted
scatterplot smoothing window) on 1 second. The fNIRS
signals will then be linearly de-trended per trial and low-
pass-filtered at 0.1 Hz to remove heart rate from the sig-
nals. To enable direct comparison of the different trials
within each task, the filtered signals will be biased, using
the average concentration of the 5 seconds before the
‘start’ instruction as a reference (zero). Then, individual
trials will be averaged per task to create three mean time
course signals per person, which will then be averaged
over all participants. Finally, the peak and mean concen-
trations (O2Hb and HHb) during the task and rest periods
will be calculated over all trials for all participants and
then averaged for each of the tasks.
Adverse events
All adverse events will be self-reported by the partici-
pants at 3, 6 and 9 weeks and assessed by the research
staff for seriousness, expectedness and causality follow-
ing the guidelines recommended by the National Health
and Medical Research Council (NHMRC) position state-
ment for monitoring and reporting of safety for clinical
trials ( https://www.nhmrc.gov.au/guidelines-publica-
tions/e112). In this study, an adverse event will be de-
fined as any health-related unfavourable or unintended
medical occurrence (sign, symptom, syndrome, illness)
that develops or worsens during the period of the trial.
Adverse events will be closely monitored until resolution
or stabilisation is achieved or until it has been shown
that the study intervention is not the cause of the injury.
Participants will be asked to contact the research staff
immediately in the event of a serious adverse event. Any
adverse event sustained during the exercise programme
will be recorded by the trainers and immediately re-
ported to the research staff. The chief investigator will
be informed of the adverse event and shall determine its
seriousness and causality in conjunction with any med-
ical staff treating the event. A serious adverse event that
is deemed related to, or suspected to be related to, the
exercise intervention will be reported to the ethics
committee.
Data management and archiving
All data will be de-identified, coded and stored on a
Deakin University server that can be accessed only
from password-protected computers. Any physical
copies of the data recording sheet will be stored in
locked filing cabinets at Deakin University (Burwood).
All data will be checked monthly by the chief investi-
gator to ensure that all protocols and ethical gu-
idelines for data collection and analysis are followed.
All study-related documents will be archived at Dea-
kin University at the end of the study for a minimum
of 6 years, which is in line with current ethical
requirements.
Dissemination plan
Findings derived from the primary outcome analysis of
this trial will be reported in journal articles, which will
include results regardless of the direction or magnitude
of the effect. The results will also be presented at leading
national and international conferences and clinical for-
ums and to other relevant health professionals and
stakeholders, as well as to the participants. All investiga-
tors will have the opportunity to be listed as an author
of future publications, in accordance with the Australian
Government National Health and Medical Research
Council guidelines [60].
Sample size calculation and statistical analysis
Gait speed, static balance and UPDRS-III at T6 will
serve as primary outcome measures, with all other as-
sessments and time points serving as secondary outcome
measures. Based on the effect size observed in a recent
study using a-tDCS during walking exercise [24], it is es-
timated that 42 participants randomised equally to three
groups will be needed. Fourteen participants in each
intervention group (a-tDCS, sham, control) will provide
at least 80 % power to detect a 10–15 % difference in
gait speed and static balance (centre of pressure), assum-
ing a 5 % significance level. In functional assessments, a
10–15 % difference equates to an increase of 5.2 points
on the UPDRS-III, which indicates a moderate clinically
important difference [61].
A two-way, repeated-measures, mixed-design analysis of
variance with factors time (T0 vs. T3 vs. T6 vs. T9) and
treatment (a-tDCS vs. sham vs. control) will be used to de-
termine any effect of the intervention on balance, gait
speed and measures of brain physiology. False discovery
rate analysis will be applied to determine when and where
significance is found. An alpha level of P < 0.05 will be set
to determine significance.
Where possible, we will obtain endpoint measures
from all withdrawals and will include all randomised
subjects in the final analysis. For participants who are
lost to follow-up, missing data will be handled with mul-
tiple imputation. As this approach makes an untestable
assumption that data are missing at random (i.e., missing
data can be predicted from the observed data) [62], we
will perform sensitivity analysis to evaluate the effect of
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potential non-random attrition [63]. Sensitivity analyses
will employ simulation and will test a range of scenarios
assuming plausible arm-specific differences in outcomes
for individuals who were lost to follow-up [64].
Discussion
To our knowledge, this pilot study will be the first ran-
domised controlled trial to combine functional PRT and
a-tDCS of the M1 to target balance and gait in people
with PD. The study has been designed to elucidate the
functional, clinical and neurophysiological outcomes of
combined PRT and a-tDCS. It is hypothesised that the
combination of PRT and a-tDCS will benefit lower limb
strength, postural sway, gait speed and stride variability
by a greater magnitude than PRT with sham-tDCS.
Further, we hypothesise that PFC activation during dual-
task cognitive and gait-and-balance activities will be
reduced, and that M1 corticospinal excitability and in-
hibition will be augmented, following the combined PRT
and a-tDCS intervention.
The study is strengthened by a double-blind approach to
tDCS stimulation type (a-tDCS or sham), with participants,
outcome assessors and exercise supervisors remaining un-
aware of stimulation type for the duration of the study. Be-
cause of the nature of the exercise interventions,
participants in the control group cannot be blinded; how-
ever, outcome assessors will remain unaware of allocation.
The PRT programme used in this study has been devel-
oped specifically to target lower limb strength and incorp-
orate functional balance tasks that will maximise gains in
mobility and reduce postural sway. All PRT sessions will
be conducted one-to-one with an experienced exercise
physiologist to ensure each participant will be trained con-
sistently. Progressions will be administered according to
individual performance and will be recorded in detail to
enable a post-intervention comparison, which will allow
us to detect any potential inequality of exercise load be-
tween groups. Outcome measures have been carefully se-
lected to enable us to detect functionally and clinically
relevant effects of the intervention (UPDRS, TUG, FTSTS,
Berg Balance Scale and 1RM lower limb strength tests), as
well as to provide sensitive biomechanical analysis with
previously validated techniques (step velocity, duration,
length, double-support time, stride width and centre-of-
pressure travel velocity). Neurophysiological assessments
will provide insight into adaptive plasticity that may
underpin any changes in functional capability, with TMS
used to detect changes in corticospinal excitability and in-
hibition of the M1 lower limb representation and fNIRS
neuroimaging of the PFC used during combined cognitive
and motor tasks to quantify changes in PFC activation.
A limitation of this study is the reduced sample size,
which has been selected for the feasibility of conducting
a one-to-one, 6-week exercise intervention. Despite this,
sample size calculations indicate that any clinically sig-
nificant benefits of combining a-tDCS with PRT will be
detected statistically. If successful, pilot data from this
study are vital to informing larger-scale clinical trials in
patients with PD, and the additional investigation of
underpinning neurophysiological mechanisms may also
be translated to inform future treatment options for a
range of other movement disorders.
The safe and inexpensive nature of a-tDCS is well
suited for translation to existing and established PD re-
habilitation programmes and services. While current
pharmacological treatments in PD provide significant
benefits to reduce the impact of some motor symptoms,
bradykinesia and impaired postural stability often con-
tinue to impact patients significantly [3]. These symp-
toms have a detrimental effect of the quality of life of
patients with PD and contribute to an increased risk of
falls [4]. Rates of falls among patients with PD are twice
as high as those in the general older population, with 46
% of people with PD experiencing recurrent falls each
year [65, 66]. Falls often result in hospitalisation [67] as
well as longer-term injuries such as fractures that further
restrict physical capability and contribute to a cycle of
secondary health complications and a loss of independ-
ence [68]. Effective interventions targeting balance and
gait will reduce the burden of PD on the individual,
family and carers, as well as the healthcare system. We
anticipate that the findings of this study will inform
large-scale randomised controlled trials aimed at imple-
menting PRT and a-tDCS in community- and home-
based settings to treat the motor symptoms of PD.
Trial status
Seventeen participants have completed the protocol in
full, and six are currently undergoing PRT. One partici-
pant has failed to complete the intervention due to ill-
ness. Recruitment of participants is ongoing.
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